Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Xenon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 98Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CHEST Study: Xenon MRI Predicts Cystic Fibrosis Exacerbations
    CHEST Study: Xenon MRI Predicts Cystic Fibrosis Exacerbations

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216892/0/en/Polarean-Highlights-New-CHEST-Journal-Study-Demonstrating-Xenon-MRI-Predicts-Cystic-Fibrosis-Exacerbations.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Xenon Highlights 2026 Milestones At J.P. Morgan Health Conference
    Xenon Highlights 2026 Milestones At J.P. Morgan Health Conference

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216905/33485/en/Xenon-Outlines-Key-Upcoming-Milestones-at-the-2026-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Xenon Presents 48-Month Azetukalner OLE Data for Epilepsy at AES
    Xenon Presents 48-Month Azetukalner OLE Data for Epilepsy at AES

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200741/33485/en/Xenon-Showcases-New-48-Month-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    Xenon To Unveil Azetukalner OLE Study Results In Epilepsy At AES
    Xenon To Unveil Azetukalner OLE Study Results In Epilepsy At AES

    25 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3194314/33485/en/Xenon-to-Present-New-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html

    GLOBENEWSWIRE
    25 Nov 2025
    Share Share
    Xenon appoints Darren Cline as Chief Commercial Officer
    Xenon appoints Darren Cline as Chief Commercial Officer

    24 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/24/3104214/33485/en/Xenon-Announces-Appointment-of-Darren-Cline-as-Chief-Commercial-Officer.html

    GLOBENEWSWIRE
    24 Jun 2025
    Share Share
    Xenon to Present at Stifel 2025 Virtual CNS Forum
    Xenon to Present at Stifel 2025 Virtual CNS Forum

    12 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/12/3041733/33485/en/Xenon-to-Present-at-Stifel-2025-Virtual-CNS-Forum.html

    GLOBENEWSWIRE
    12 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.